Osteoclasts are essential for TNF-?????mediated joint destruction, Journal of Clinical Investigation, vol.110, issue.10, pp.1419-1427, 2002. ,
DOI : 10.1172/JCI0215582
Erosive arthritis, Arthritis Research & Therapy, vol.9, issue.Suppl 1, p.2, 2007. ,
DOI : 10.1186/ar2166
URL : http://doi.org/10.1186/ar2166
Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis, Am J Pathol, vol.152, pp.943-951, 1998. ,
TRANCE/RANKL Knockout Mice Are Protected from Bone Erosion in a Serum Transfer Model of Arthritis, The American Journal of Pathology, vol.159, issue.5, pp.1689-1699, 2001. ,
DOI : 10.1016/S0002-9440(10)63016-7
Osteoprotegerin Reduces Osteoclast Numbers and Prevents Bone Erosion in Collagen-Induced Arthritis, The American Journal of Pathology, vol.161, issue.4, pp.1419-1427, 2002. ,
DOI : 10.1016/S0002-9440(10)64417-3
RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis, Rheumatology, vol.45, issue.9, pp.1068-1076, 2006. ,
DOI : 10.1093/rheumatology/kel045
Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment, Blood, vol.104, issue.13, pp.4029-4037, 2004. ,
DOI : 10.1182/blood-2004-01-0041
Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates, Best Practice & Research Clinical Rheumatology, vol.19, issue.6, pp.1065-1079, 2005. ,
DOI : 10.1016/j.berh.2005.06.008
Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial, Arthritis & Rheumatism, vol.27, issue.5, pp.1299-1309, 2008. ,
DOI : 10.1002/art.23417
Bisphosphonates: new therapeutic agents for the treatment of bone tumors, Trends in Molecular Medicine, vol.10, issue.7, pp.337-343, 2004. ,
DOI : 10.1016/j.molmed.2004.05.007
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial, The Lancet, vol.373, issue.9671, pp.1253-1263, 2009. ,
DOI : 10.1016/S0140-6736(09)60250-6
Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis, Arthritis & Rheumatism, vol.44, issue.Suppl 6, pp.2327-2337, 2004. ,
DOI : 10.1002/art.20384
Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis, Arthritis & Rheumatism, vol.3, issue.7, pp.2338-2346, 2004. ,
DOI : 10.1002/art.20382
Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis, Arthritis & Rheumatism, vol.61, issue.5, pp.1410-1414, 2006. ,
DOI : 10.1002/art.21824
Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate, Archives of Internal Medicine, vol.159, issue.21, pp.2542-2550, 1999. ,
DOI : 10.1001/archinte.159.21.2542
The effectiveness of anti???tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: A population-based study, Arthritis & Rheumatism, vol.38, issue.1, pp.54-59, 2006. ,
DOI : 10.1002/art.21491
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis, New England Journal of Medicine, vol.343, issue.22, pp.1586-1593, 2000. ,
DOI : 10.1056/NEJM200011303432201
Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor ?B, osteoprotegerin, and receptor activator of nuclear factor ?B ligand, Arthritis & Rheumatism, vol.250, issue.12, pp.3831-3843, 2004. ,
DOI : 10.1002/art.20637
Damaging effects of chronic low-dose methotrexate usage on primary bone formation in young rats and potential protective effects of folinic acid supplementary treatment, Bone, vol.44, issue.1, pp.61-70, 2009. ,
DOI : 10.1016/j.bone.2008.09.014
MTX affects inflammation and tissue destruction differently in the rat AA model, J Rheumatol, vol.28, pp.1476-1481, 2001. ,
Measurement of radiographic changes in adjuvant-induced arthritis in rats by quantitative image analysis, Arthritis & Rheumatism, vol.29, issue.1, pp.129-138, 1995. ,
DOI : 10.1002/art.1780380120
downregulates autoimmune reactivity through active transforming growth factor-beta production in collagen-induced arthritis, J Clin Invest, vol.112, pp.69872-882, 2003. ,
Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial, Arthritis & Rheumatism, vol.23, issue.3, pp.396-402, 1996. ,
DOI : 10.1002/art.1780390307
Double Blind Radiological Assessment of Continuous Oral Pamidronic Acid in Patients with Rheumatoid Arthritis, Scandinavian Journal of Rheumatology, vol.17, issue.1, pp.211-214, 1994. ,
DOI : 10.1016/0140-6736(90)90452-B
Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease, J Rheumatol, vol.30, pp.468-473, 2003. ,
Long-Term Protective Effects of Zoledronic Acid on Cancellous and Cortical Bone in the Ovariectomized Rat, Journal of Bone and Mineral Research, vol.21, issue.Suppl, pp.544-551, 2008. ,
DOI : 10.1359/jbmr.071207
Effects of bisphosphonates on joint damage and bone loss in rat adjuvant-induced arthritis, Inflammation Research, vol.53, issue.2, pp.45-52, 2004. ,
DOI : 10.1007/s00011-003-1214-4
Methotrexate suppresses inflammatory agonist induced interleukin 6 synthesis in osteoblasts, J Rheumatol, vol.32, pp.787-795, 2005. ,
Molecular action of methotrexate in inflammatory diseases, Arthritis Research, vol.4, issue.4, pp.266-273, 2002. ,
DOI : 10.1186/ar419
Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis, Pharmacological Reviews, vol.57, issue.2, pp.163-172, 2005. ,
DOI : 10.1124/pr.57.2.3
Short-term low dose methotrexate ameliorates abnormal bone metabolism and bone loss in adjuvant induced arthritis, J Rheumatol, vol.24, pp.1890-1895, 1997. ,
Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission, Cancer, vol.72, issue.3, pp.580-585, 1970. ,
DOI : 10.1002/1097-0142(197003)25:3<580::AID-CNCR2820250313>3.0.CO;2-M
The Effect of Low-Dose Methotrexate on Bone Metabolism and Histomorphometry in Rats, Arthritis & Rheumatism, vol.20, issue.2, pp.201-206, 1994. ,
DOI : 10.1002/art.1780370208
The short- and long-term effects of methotrexate on the rat skeleton, Bone, vol.16, issue.2, pp.215-221, 1995. ,
DOI : 10.1016/8756-3282(94)00032-U
Methotrexate osteopathy, Skeletal Radiology, vol.125, issue.1, pp.13-16, 1984. ,
DOI : 10.1007/BF00361126
Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study, J Rheumatol, vol.31, pp.1305-1309, 2004. ,
The effect of low dose methotrexate on bone density, J Rheumatol, vol.28, pp.2395-2399, 2001. ,
Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density, Rheumatology, vol.41, issue.7, pp.741-749, 2002. ,
DOI : 10.1093/rheumatology/41.7.741
Density and structural changes in the bone of growing rats after weekly alendronate administration with and without a methotrexate challenge, Journal of Orthopaedic Research, vol.15, issue.5, pp.936-944, 2006. ,
DOI : 10.1002/jor.20145
Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids, Rheumatology International, vol.20, issue.2, pp.65-69, 2001. ,
DOI : 10.1007/s002960000080